KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Net Income (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 17 years of Net Income data on record, last reported at $1.2 billion in Q4 2025.

  • For Q4 2025, Net Income rose 30.46% year-over-year to $1.2 billion; the TTM value through Dec 2025 reached $4.0 billion, up 838.09%, while the annual FY2025 figure was $4.0 billion, 838.09% up from the prior year.
  • Net Income reached $1.2 billion in Q4 2025 per VRTX's latest filing, up from $1.1 billion in the prior quarter.
  • Across five years, Net Income topped out at $1.2 billion in Q4 2025 and bottomed at -$3.6 billion in Q2 2024.
  • Average Net Income over 5 years is $635.1 million, with a median of $882.5 million recorded in 2021.
  • Peak YoY movement for Net Income: skyrocketed 1109.7% in 2022, then tumbled 492.44% in 2024.
  • A 5-year view of Net Income shows it stood at $770.1 million in 2021, then rose by 6.34% to $818.9 million in 2022, then increased by 18.31% to $968.8 million in 2023, then decreased by 5.76% to $913.0 million in 2024, then skyrocketed by 30.46% to $1.2 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Net Income were $1.2 billion in Q4 2025, $1.1 billion in Q3 2025, and $1.0 billion in Q2 2025.